MRTX logo

Mirati Therapeutics (MRTX) Free Cash Flow

Annual FCF

-$575.42 M
-$176.83 M-44.36%

31 December 2022

MRTX Free Cash Flow Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly FCF

-$143.75 M
-$11.63 M-8.80%

30 September 2023

MRTX Quarterly FCF Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM FCF

-$595.93 M
-$4.70 M-0.79%

30 September 2023

MRTX TTM FCF Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

MRTX Free Cash Flow Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year---
3 y3 years-44.4%-2.2%-49.5%
5 y5 years-285.5%-232.5%-299.2%

MRTX Free Cash Flow High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years
5 y5 years
alltimeall time-5558.3%-1030.9%-5752.8%

Mirati Therapeutics Free Cash Flow History

DateAnnualQuarterlyTTM
Sept 2023
-
-$143.75 M(+8.8%)
-$595.93 M(+0.8%)
June 2023
-
-$132.12 M(-30.6%)
-$591.23 M(-2.2%)
Mar 2023
-
-$190.45 M(+46.9%)
-$604.26 M(+5.0%)
Dec 2022
-$575.42 M(+44.4%)
-$129.61 M(-6.8%)
-$575.42 M(-1.9%)
Sept 2022
-
-$139.05 M(-4.2%)
-$586.45 M(+18.1%)
June 2022
-
-$145.15 M(-10.2%)
-$496.44 M(+10.6%)
Mar 2022
-
-$161.61 M(+14.9%)
-$448.68 M(+12.6%)
Dec 2021
-$398.60 M(+44.5%)
-$140.63 M(+186.8%)
-$398.60 M(+18.7%)
Sept 2021
-
-$49.04 M(-49.6%)
-$335.89 M(-8.0%)
June 2021
-
-$97.40 M(-12.7%)
-$365.05 M(+11.2%)
Mar 2021
-
-$111.52 M(+43.1%)
-$328.19 M(+19.0%)
Dec 2020
-$275.90 M(+84.8%)
-$77.93 M(-0.3%)
-$275.90 M(+14.4%)
Sept 2020
-
-$78.20 M(+29.2%)
-$241.21 M(+23.0%)
June 2020
-
-$60.54 M(+2.2%)
-$196.03 M(+12.6%)
Mar 2020
-
-$59.23 M(+37.0%)
-$174.02 M(+16.6%)
Dec 2019
-$149.28 M(+112.6%)
-$43.23 M(+30.9%)
-$149.28 M(+17.6%)
Sept 2019
-
-$33.02 M(-14.3%)
-$126.92 M(+11.2%)
June 2019
-
-$38.54 M(+11.8%)
-$114.11 M(+17.9%)
Mar 2019
-
-$34.48 M(+65.1%)
-$96.75 M(+37.8%)
Dec 2018
-$70.22 M(+8.4%)
-$20.88 M(+3.3%)
-$70.22 M(+11.3%)
Sept 2018
-
-$20.21 M(-4.6%)
-$63.10 M(+8.8%)
June 2018
-
-$21.18 M(+166.5%)
-$57.99 M(+6.4%)
Mar 2018
-
-$7.95 M(-42.3%)
-$54.50 M(-15.9%)
Dec 2017
-$64.79 M(-5.0%)
-$13.77 M(-8.8%)
-$64.79 M(-3.7%)
Sept 2017
-
-$15.09 M(-14.7%)
-$67.28 M(-4.6%)
June 2017
-
-$17.70 M(-2.9%)
-$70.50 M(+1.5%)
Mar 2017
-
-$18.23 M(+12.2%)
-$69.45 M(+1.8%)
Dec 2016
-$68.21 M(+33.6%)
-$16.26 M(-11.2%)
-$68.21 M(+0.3%)
Sept 2016
-
-$18.32 M(+10.0%)
-$68.02 M(+3.7%)
June 2016
-
-$16.64 M(-2.1%)
-$65.57 M(+12.6%)
Mar 2016
-
-$17.00 M(+5.8%)
-$58.25 M(+14.1%)
Dec 2015
-$51.04 M(+54.1%)
-$16.06 M(+1.2%)
-$51.04 M(+17.0%)
Sept 2015
-
-$15.87 M(+70.3%)
-$43.63 M(+16.6%)
June 2015
-
-$9.32 M(-4.9%)
-$37.44 M(+9.7%)
Mar 2015
-
-$9.79 M(+13.2%)
-$34.13 M(+3.0%)
Dec 2014
-$33.13 M
-$8.65 M(-10.5%)
-$33.13 M(+2.9%)
Sept 2014
-
-$9.67 M(+61.0%)
-$32.20 M(+16.0%)
June 2014
-
-$6.01 M(-31.7%)
-$27.76 M(-10.5%)
DateAnnualQuarterlyTTM
Mar 2014
-
-$8.80 M(+14.0%)
-$31.03 M(+4.6%)
Dec 2013
-$29.66 M(+75.7%)
-$7.72 M(+47.5%)
-$29.66 M(+8.7%)
Sept 2013
-
-$5.24 M(-43.6%)
-$27.29 M(+3.9%)
June 2013
-
-$9.27 M(+24.8%)
-$26.25 M(+32.3%)
Mar 2013
-
-$7.43 M(+38.9%)
-$19.85 M(+17.6%)
Dec 2012
-$16.88 M(+47.7%)
-$5.35 M(+27.3%)
-$16.88 M(+11.1%)
Sept 2012
-
-$4.20 M(+46.5%)
-$15.19 M(+13.1%)
June 2012
-
-$2.87 M(-35.8%)
-$13.44 M(+4.2%)
Mar 2012
-
-$4.46 M(+21.9%)
-$12.89 M(+12.8%)
Dec 2011
-$11.43 M(-27.3%)
-$3.66 M(+49.5%)
-$11.43 M(+11.8%)
Sept 2011
-
-$2.45 M(+5.5%)
-$10.22 M(-15.3%)
June 2011
-
-$2.32 M(-22.8%)
-$12.08 M(-3.9%)
Mar 2011
-
-$3.00 M(+22.5%)
-$12.57 M(-20.1%)
Dec 2010
-$15.73 M(-23.3%)
-$2.45 M(-43.0%)
-$15.73 M(-4.4%)
Sept 2010
-
-$4.30 M(+53.0%)
-$16.46 M(-12.5%)
June 2010
-
-$2.81 M(-54.4%)
-$18.80 M(-11.9%)
Mar 2010
-
-$6.17 M(+94.1%)
-$21.35 M(+4.1%)
Dec 2009
-$20.50 M(+10.1%)
-$3.18 M(-52.1%)
-$20.50 M(+8.9%)
Sept 2009
-
-$6.64 M(+24.0%)
-$18.84 M(+10.2%)
June 2009
-
-$5.36 M(+0.7%)
-$17.09 M(-4.3%)
Mar 2009
-
-$5.32 M(+252.2%)
-$17.86 M(-4.1%)
Dec 2008
-$18.63 M(-22.3%)
-$1.51 M(-69.1%)
-$18.63 M(-24.8%)
Sept 2008
-
-$4.90 M(-20.2%)
-$24.79 M(+4.6%)
June 2008
-
-$6.13 M(+0.7%)
-$23.71 M(-4.9%)
Mar 2008
-
-$6.09 M(-20.6%)
-$24.94 M(+4.0%)
Dec 2007
-$23.97 M(-327.4%)
-$7.67 M(+100.9%)
-$23.97 M(+28.4%)
Sept 2007
-
-$3.82 M(-48.2%)
-$18.67 M(+43.5%)
June 2007
-
-$7.36 M(+43.7%)
-$13.00 M(+29.7%)
Mar 2007
-
-$5.13 M(+117.2%)
-$10.02 M(-195.1%)
Dec 2006
$10.54 M(-183.3%)
-$2.36 M(-227.8%)
$10.54 M(+1.4%)
Sept 2006
-
$1.85 M(-142.1%)
$10.40 M(+101.9%)
June 2006
-
-$4.39 M(-128.4%)
$5.15 M(-4.2%)
Mar 2006
-
$15.44 M(-716.5%)
$5.38 M(-142.5%)
Dec 2005
-$12.65 M(+85.2%)
-$2.50 M(-26.4%)
-$12.65 M(+24.7%)
Sept 2005
-
-$3.40 M(-18.2%)
-$10.15 M(+50.4%)
June 2005
-
-$4.16 M(+60.7%)
-$6.75 M(+160.7%)
Mar 2005
-
-$2.59 M
-$2.59 M
Dec 2004
-$6.83 M(-1314.2%)
-
-
Dec 2003
$562.60 K
-
-

FAQ

  • What is Mirati Therapeutics annual free cash flow?
  • What is the all time high annual FCF for Mirati Therapeutics?
  • What is Mirati Therapeutics quarterly free cash flow?
  • What is the all time high quarterly FCF for Mirati Therapeutics?
  • What is Mirati Therapeutics TTM free cash flow?
  • What is the all time high TTM FCF for Mirati Therapeutics?

What is Mirati Therapeutics annual free cash flow?

The current annual FCF of MRTX is -$575.42 M

What is the all time high annual FCF for Mirati Therapeutics?

Mirati Therapeutics all-time high annual free cash flow is $10.54 M

What is Mirati Therapeutics quarterly free cash flow?

The current quarterly FCF of MRTX is -$143.75 M

What is the all time high quarterly FCF for Mirati Therapeutics?

Mirati Therapeutics all-time high quarterly free cash flow is $15.44 M

What is Mirati Therapeutics TTM free cash flow?

The current TTM FCF of MRTX is -$595.93 M

What is the all time high TTM FCF for Mirati Therapeutics?

Mirati Therapeutics all-time high TTM free cash flow is $10.54 M